Article
Chemistry, Medicinal
Md Khalilur Rahman, Yassir Al-Zubaidi, Kirsi Bourget, Yongjuan Chen, Stanton Tam, Fanfan Zhou, Michael Murray
Summary: Long-term use of cytotoxic agents promotes drug resistance in triple-negative breast cancer. Combination analysis showed that the combination of ixabepilone with VEGFR inhibitors and PARP inhibitors effectively reduced cell viability, suggesting potential clinical applications.
JOURNAL OF PHARMACEUTICAL SCIENCES
(2022)
Article
Chemistry, Medicinal
Domiziana Masci, Michela Puxeddu, Laura Di Magno, Michele D'Ambrosio, Anastasia Parisi, Marianna Nalli, Ruoli Bai, Antonio Coluccia, Pietro Scio, Viviana Orlando, Sara D'Angelo, Stefano Biagioni, Andrea Urbani, Ernest Hamel, Alessio Nocentini, Serena Filiberti, Marta Turati, Roberto Ronca, Joanna Kopecka, Chiara Riganti, Cinzia Fionda, Rosa Bordone, Giorgia Della Rocca, Gianluca Canettieri, Claudiu T. Supuran, Romano Silvestri, Giuseppe La Regina
Summary: We synthesized new compounds as inhibitors of human carbonic anhydrase (hCA) with the potential to inhibit the Wnt/beta-catenin signaling pathway. One of the compounds, designated as compound 15, not only showed strong inhibition against hCA XII, but also suppressed the Wnt/beta-catenin signaling pathway and its target genes. It exhibited potent cytotoxicity against cancer cells.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Dana M. Roque, Eric R. Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Gautam G. Rao, Jocelyn C. Reader, Pei Hui, Joan R. Tymon-Rosario, Justin Harold, Dennis Mauricio, Burak Zeybek, Gulden Menderes, Gary Altwerger, Elena Ratner, Alessandro D. Santin
Summary: This multi-center study evaluated the activity and safety of ixabepilone plus bevacizumab compared to ixabepilone alone in platinum-resistant/refractory ovarian cancer. The results showed that the combination of ixabepilone and bevacizumab had a higher overall response rate and longer progression-free survival, with good tolerability. Prior receipt of bevacizumab should not limit the use of ixabepilone plus bevacizumab in treatment.
BRITISH JOURNAL OF CANCER
(2022)
Article
Engineering, Biomedical
Jie Yao, Tongyu Li, Xiaowei Shi, Yuchen Wang, Shijiang Fang, Hangxiang Wang
Summary: Nanohydrogels are developed as a promising platform for cancer treatment, capable of releasing active agents in response to the tumor microenvironment, and show higher safety profile and efficacy compared to traditional chemotherapy.
ACTA BIOMATERIALIA
(2021)
Article
Chemistry, Multidisciplinary
Jia-Hong Lei, Ling-Ling Ma, Jing-Hong Xian, Hai Chen, Jian-Jian Zhou, Hao Chen, Qian Lei, Yu-Yan Li, Yan-Yan Wang, Yu-Xi Wang
Summary: Microtubules composed of alpha- and beta-tubulin heterodimers are efficient drug targets for cancer therapy. Agents like ELR510444 and parbendazole can disrupt microtubule assembly by binding to tubulin at the colchicine binding site. Crystal structures of tubulin complexed with these inhibitors provide insights for designing novel compounds targeting the colchicine binding site.
Article
Oncology
Samusi Adediran, Linbo Wang, Mohammad Afnan Khan, Wei Guang, Xiaoxuan Fan, Hancai Dan, Jianfei Qi, Steven M. Jay, France Carrier, Arif Hussain
Summary: The study explores the efficacy of targeting ErbB receptors and AKT in prostate cancer, finding that simultaneous targeting is more effective than individual targeting, especially in resistant cells. This provides a new avenue for treating refractory prostate cancer.
Review
Hematology
Andrea Brendolan, Vincenzo Russo
Summary: Cholesterol homeostasis plays a crucial role in cellular functions and tumor development. Manipulating cholesterol homeostasis can affect tumor cell integrity and immune responses, making it a potential therapeutic target for hematopoietic malignancies.
Article
Chemistry, Medicinal
Yingyuan Peng, Zhixian Shi, Yuru Liang, Kuiling Ding, Yang Wang
Summary: In this study, an enzyme-responsive prodrug therapy for triple-negative breast cancer was developed based on the different b-glucuronidase levels between tumor and normal tissues. The prodrug 17a showed remarkable stability, selectivity, and potent antitumor efficacy with superior safety profiles in animal models.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Multidisciplinary Sciences
Maria J. Torres, Xu Zhang, Dorothy H. Slentz, Timothy R. Koves, Hailee Patel, George A. Truskey, Deborah M. Muoio
Summary: The two commonly used breast cancer chemotherapies, doxorubicin and docetaxel, have been found to have long-lasting side effects on cardiometabolic and musculoskeletal health. Doxorubicin affects mitochondrial function, while docetaxel remodels the microtubule network, leading to disruptions in glucose transport and respiratory control.
Article
Parasitology
Khalid M. Mohammedsalih, Juergen Kruecken, Ahmed Bashar, Fathel-Rahman Juma, Abdalhakaim A. H. Abdalmalaik, Amna Khalafalla, Adam Abakar, Gerald Coles, Georg von Samson-Himmelstjerna
Summary: This study reported reduced albendazole efficacy in cattle in Sudan and described an E198L substitution in phenotypically BZ-resistant nematodes collected from cattle, which has not been previously reported.
PARASITES & VECTORS
(2021)
Article
Biotechnology & Applied Microbiology
Fan Fei, Liang Rong, Nan Jiang, Alan S. Wayne, Jianming Xie
Summary: In this study, an anti-HLA-DR inhibitory CAR (iCAR) was developed to effectively suppress NK cell activation against HLA-DR-expressing cells. Dual CAR-NK cells, which co-express the anti-CD19 or CD33 activating CAR and the anti-HLA-DR iCAR, were found to preferentially target HLA-DR-negative cells over HLA-DR-positive cells in vitro. The HLA-DR-mediated inhibition was positively correlated with both iCAR and HLA-DR densities. HLA-DR-positive cells were resistant to dual CAR-NK cell-mediated killing in a xenograft mouse model, confirming the potential of this approach to enhance CAR-NK and CAR-T cell specificity against malignancies with HLA-DR loss.
Article
Oncology
Sol-Bi Shin, Dae-Hoon Kim, Da-Eun Kim, Mark Borris D. Aldonza, Yoosik Kim, Hyungshin Yim
Summary: Our study suggests that targeting PLK1 can overcome taxane resistance by downregulating ABC transporters in LUAD(TXR), especially when combined with gefitinib. The combination treatment shows strong synergism in inducing apoptosis in LUAD(TXR) cells through c-Myc or AP-1, providing a potential strategy to improve outcomes in LUAD patients. Clinical data support the relationship between survival rates and expressions of PLK1 and EGFR, highlighting the importance of combination therapies in overcoming chemoresistance.
Article
Multidisciplinary Sciences
Hiroshi Hongo, Takeo Kosaka, Yoko Suzuki, Shuji Mikami, Junichi Fukada, Mototsugu Oya
Summary: The study identified etoposide as a promising treatment candidate for CBZ-resistant CRPC by inhibiting TOP2A expression, which could potentially be an optimal treatment for CRPC in the post-CBZ setting.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Torben Johann Hausrat, Philipp C. Janiesch, Petra Breiden, David Lutz, Sabine Hoffmeister-Ullerich, Irm Hermans-Borgmeyer, Antonio Virgilio Failla, Matthias Kneussel
Summary: The loss of tubulin a4 polyglutamylation reverses tau hyperphosphorylation, oligomerization, and microglia activation in a tauopathy mouse model, highlighting tubulin polyglutamylation as a potential therapeutic strategy in fighting tauopathies.
NATURE COMMUNICATIONS
(2022)
Article
Chemistry, Medicinal
Shiyuan Fang, Shijie Bi, Yannan Li, Shuai Tian, Huixin Xu, Lei Fu, Shixiao Wang, Yu Tang, Peiju Qiu
Summary: Plinabulin is a promising microtubule destabilizing agent in phase 3 clinical stage for treating non-small cell lung cancer. However, its high toxicity and poor water solubility limit its use and the exploration of more plinabulin derivatives. In this study, two series of 29 plinabulin derivatives were designed, synthesized, and evaluated for their anti-tumor effect against three types of cancer cell lines. Compound 11c showed stronger efficiency than plinabulin due to an additional hydrogen bond formation, disrupted tubulin structure, and induced cell cycle arrest and apoptosis. Compound 11c could be a potential candidate for cancer treatment as an antimicrotubule agent.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2023)
Review
Oncology
Muhammad-Zawwad Raza, Simone Allegrini, Charles Dumontet, Lars Petter Jordheim
GENES CHROMOSOMES & CANCER
(2018)
Article
Oncology
Xiaomu Wei, M. Nieves Calvo-Vidal, Siwei Chen, Gang Wu, Maria V. Revuelta, Jian Sun, Jinghui Zhang, Michael F. Walsh, Kim E. Nichols, Vijai Joseph, Carrie Snyder, Celine M. Vachon, James D. Mckay, Shu-Ping Wang, David S. Jayabalan, Lauren M. Jacobs, Dina Becirovic, Rosalie G. Waller, Mykyta Artomov, Agnes Viale, Jayeshkumar Patel, Jude Phillip, Selina Chen-Kiang, Karen Curtin, Mohamed Salama, Djordje Atanackovic, Ruben Niesvizky, Ola Landgren, Susan L. Slager, Lucy A. Godley, Jane Churpek, Judy E. Garber, Kenneth C. Anderson, Mark J. Daly, Robert G. Roeder, Charles Dumontet, Henry T. Lynch, Charles G. Mullighan, Nicola J. Camp, Kenneth Offit, Robert J. Klein, Haiyuan Yu, Leandro Cerchietti, Steven M. Lipkin
Article
Pharmacology & Pharmacy
Lars Petter Jordheim, Kamel Chettab, Emeline Cros-Perrial, Eva-Laure Matera, Charles Dumontet
Article
Oncology
Daniele Campa, Alessandro Martino, Angelica Macauda, Marek Dudzinski, Anna Suska, Agnieszka Druzd-Sitek, Marc-Steffen Raab, Victor Moreno, Stefanie Huhn, Aleksandra Butrym, Juan Sainz, Gergely Szombath, Marcin Rymko, Herlander Marques, Fabienne Lesueur, Annette Juul Vangsted, Ulla Vogel, Marcin Kruszewski, Edyta Subocz, Gabriele Buda, Elzbieta Iskierka-Jazdzewska, Rafael Rios, Maximilian Merz, Ben Schoettker, Grzegorz Mazur, Emeline Perrial, Joaquin Martinez-Lopez, Katja Butterbach, Ramon Garcia Sanz, Hartmut Goldschmidt, Hermann Brenner, Krzysztof Jamroziak, Rui Manuel Reis, Katalin Kadar, Charles Dumontet, Marzena Watek, Eva Kannik Haastrup, Grzegorz Helbig, Artur Jurczyszyn, Andres Jerez, Judit Varkonyi, Torben Barington, Norbert Grzasko, Jan Maciej Zaucha, Vibeke Andersen, Daria Zawirska, Federico Canzian
LEUKEMIA & LYMPHOMA
(2019)
Article
Biochemical Research Methods
Christian Klein, Wolfgang Schaefer, Joerg T. Regula, Charles Dumontet, Ulrich Brinkmann, Marina Bacac, Pablo Umana
Article
Hematology
Caroline Sut, Hind Hamzeh-Cognasse, Charles-Antoine Arthaud, Marie-Ange Eyraud, Kamel Chettab, Charles Dumontet, Sandrine Laradi, Thierry Burnouf, Olivier Garraud, Fabrice Cognasse
Article
Immunology
Chloe Grasselly, Morgane Denis, Aurora Bourguignon, Nolan Talhi, Doriane Mathe, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Eva Laure Matera, Charles Dumontet
FRONTIERS IN IMMUNOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Ghina Alameh, Agnes Emptoz-Bonneton, Marc Rolland de Ravel, Eva L. Matera, Elisabeth Mappus, Patrick Balaguer, Luc Rocheblave, Thierry Lomberget, Charles Dumontet, Marc Le Borgne, Michel Pugeat, Catherine Grenot, Claude Y. Cuilleron
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
(2019)
Article
Chemistry, Medicinal
Remi Guillon, Rahila Rahimova, Preeti, David Egron, Sonia Rouanet, Charles Dumontet, Nushin Aghajari, Lars Petter Jordheim, Laurent Chaloin, Suzanne Peyrottes
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2019)
Letter
Oncology
Maroulio Pertesi, Maxime Vallee, Xiaomu Wei, Maria V. Revuelta, Perrine Galia, Delphine Demangel, Javier Oliver, Matthieu Foll, Siwei Chen, Emeline Perrial, Laurent Garderet, Jill Corre, Xavier Leleu, Eileen M. Boyle, Olivier Decaux, Philippe Rodon, Brigitte Kolb, Borhane Slama, Philippe Mineur, Eric Voog, Catherine Le Bris, Jean Fontan, Michel Maigre, Marie Beaumont, Isabelle Azais, Hagay Sobol, Marguerite Vignon, Bruno Royer, Aurore Perrot, Jean-Gabriel Fuzibet, Veronique Dorvaux, Bruno Anglaret, Pascale Cony-Makhoul, Christian Berthou, Florence Desquesnes, Brigitte Pegourie, Serge Leyvraz, Laurent Mosser, Nicole Frenkiel, Karine Augeul-Meunier, Isabelle Leduc, Cecile Leyronnas, Laurent Voillat, Philippe Casassus, Claire Mathiot, Nathalie Cheron, Etienne Paubelle, Philippe Moreau, Yves-Jean Bignon, Bertrand Joly, Pascal Bourquard, Denis Caillot, Herve Naman, Sophie Rigaudeau, Gerald Marit, Margaret Macro, Isabelle Lambrecht, Manuel Cliquennois, Laure Vincent, Philippe Helias, Herve Avet-Loiseau, Victor Moreno, Rui Manuel Reis, Judit Varkonyi, Marcin Kruszewski, Annette Juul Vangsted, Artur Jurczyszyn, Jan Maciej Zaucha, Juan Sainz, Malgorzata Krawczyk-Kulis, Marzena Watek, Matteo Pelosini, Elzbieta Iskierka-Jazdzewska, Norbert Grzasko, Joaquin Martinez-Lopez, Andres Jerez, Daniele Campa, Gabriele Buda, Fabienne Lesueur, Marek Dudzinski, Ramon Garcia-Sanz, Arnon Nagler, Marcin Rymko, Krzysztof Jamroziak, Aleksandra Butrym, Federico Canzian, Ofure Obazee, Bjorn Nilsson, Robert J. Klein, Steven M. Lipkin, James D. McKay, Charles Dumontet
Letter
Oncology
Yesim Dargaud, Marc Fouassier, Jean Claude Bordet, Sophie Ducastelle-Lepretre, Charles Dumontet, Philippe Moreau, Mauricette Michallet
LEUKEMIA & LYMPHOMA
(2019)
Article
Chemistry, Multidisciplinary
Warren Viricel, Guy Fournet, Sabine Beaumel, Emeline Perrial, Sebastien Papot, Charles Dumontet, Benoit Joseph
Article
Oncology
Camille Lehuede, Xia Li, Stephanie Dauvillier, Charlotte Vaysse, Camille Franchet, Emily Clement, David Esteve, Melanie Longue, Leonor Chaltiel, Sophie Le Gonidec, Ikrame Lazar, Aline Geneste, Charles Dumontet, Philippe Valet, Laurence Nieto, Frederique Fallone, Catherine Muller
BREAST CANCER RESEARCH
(2019)
Article
Biochemical Research Methods
David Kryza, Gabriel De Crozals, Doriane Mathe, Jacqueline Taleb Sidi-Boumedine, Marc Janier, Carole Chaix, Charles Dumontet
BIOCONJUGATE CHEMISTRY
(2018)
Article
Biochemical Research Methods
Gabriel De Crozals, David Kryza, Gloria Jimenez Sanchez, Stephane Roux, Doriane Mathe, Jacqueline Taleb, Charles Dumontet, Marc Janier, Carole Chaix
BIOCONJUGATE CHEMISTRY
(2018)